[1]Fisher M, Golestaneh L, Allon M, et al. Prevention of bloodstream infections in patients undergoing hemodialysis[J]. Clin J Am Soc Nephrol, 2020, 15(1): 132-151.
[2]Poinen K, Quinn RR, Clarke A, et al. Complications from tunneled hemodialysis catheters: a Canadian observational cohort study[J]. Am J Kidney Dis, 2019, 73(4): 467-475.
[3]Hasanoglu I, Guner R, Sahin S, et al. Surveillance of hemodialysis related infections: a prospective multicenter study[J]. Sci Rep, 2022, 12(1): 22240.
[4]Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheterrelated infection: 2009 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 49(1): 1-45.
[5]Sahli F, Feidjel R, Laalaoui R. Hemodialysis catheterrelated infection: rates, risk factors and pathogens[J]. J Infect Public Health, 2017, 10(4): 403-408.
[6]马曦立, 刘霞, 吴鑫, 等. 慢性肾功能衰竭血液透析导管相关性血流感染病原菌耐药性及其影响因素[J]. 中华医院感染学杂志, 2021, 31(3): 385-389.
[7]沈华娟, 许秀君, 董永泽, 等. 血液透析患者导管相关性血流感染影响因素[J]. 中华医院感染学杂志, 2020, 30(20): 3104-3107.
[8]Allon M. Dialysis catheterrelated bacteremia: treatment and prophylaxis[J]. Am J Kidney Dis, 2004, 44(5): 779-791.
[9]O′Grady NP. Prevention of central lineassociated bloodstream infections[J]. N Engl J Med, 2023, 389(12): 1121-1131.
[10]Buetti N, Marschall J, Drees M, et al. Strategies to prevent central lineassociated bloodstream infections in acutecare hospitals: 2022 Update[J]. Infect Control Hosp Epidemiol, 2022, 43(5): 553-569.
[11]Kiyoshi M, Tadao A, Mariko K, et al. Risk factors associated with increased incidences of catheterrelated bloodstream infection[J]. Medicine, 2022, 101(42): e31160.
[12]Lafuente Cabrero E, Terradas Robledo R, Civit Cuado A, et al. Risk factors of catheterassociated bloodstream infection: Systematic review and metaanalysis[J]. PLoS One, 2023, 18(3): e282290.
[13]Tanaka S, Couret D, TranDinh A, et al. Highdensity lipoproteins during sepsis: from bench to bedside[J]. Crit Care, 2020, 24(1): 134.
[14]余姝, 华琴, 朱文芳, 等. 透析前慢性肾脏病门诊管理对维持性血液透析患者的益处[J]. 中国血液净化, 2018, 17(8): 529-533.
[15]Selby LM, Rupp ME, Cawcutt KA. Prevention of centralline associated bloodstream infections: 2021 update[J]. Infect Dis Clin North Am, 2021, 35(4): 841-856.
[16]See I, Shugart A, Lamb C, et al. Infection control and bloodstream infection prevention: the perspective of patients receiving hemodialysis[J]. Nephrol Nurs J, 2014, 41(1): 37-39.
[17]Shun M, Atsushi N, Takahiro I, et al. Low serum albumin as a risk factor for infectionrelated inhospital death among hemodialysis patients hospitalized on suspicion of infectious disease: a Japanese multicenter retrospective cohort study[J]. Ren Replace Ther, 2018, 4(1): 30.
[18]李道新, 熊飞, 李红波, 等. 维持性血液透析患者微炎症状态及外周血Keap1Nrf2ARE表达对导管相关性血流感染的诊断价值[J]. 中华医院感染学杂志, 2023, 33(1): 49-53.
[19]何雪, 殷芳. 左卡尼汀联合金水宝治疗维持性血液透析慢性肾功能衰竭患者的临床效果观察[J]. 江苏大学学报(医学版), 2022, 32(2): 156-160, 166.
|